C4 Therapeutics Inc (CCCC) concluded trading on Thursady at a closing price of $8.80, with 6.9 million shares of worth about $60.74 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 170.77% during that period and on Thursady the price saw a gain of about 21.38%. Currently the company’s common shares owned by public are about 48.97M shares, out of which, 38.41M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 23 times over the past 12 months. They bought 150,199 shares in 17 of the transactions. In 6 selling transactions, insiders dumped 5,510 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 8.98, or with a gain of 21.38%. Stock saw a price change of 20.38% in past 5 days and over the past one month there was a price change of 56.03%. Year-to-date (YTD), CCCC shares are showing a performance of 55.75% which increased to 53.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.06 but also hit the highest price of $8.42 during that period. The average intraday trading volume for C4 Therapeutics Inc shares is 15.48 million. The stock is currently trading 39.82% above its 20-day simple moving average (SMA20), while that difference is up 52.67% for SMA50 and it goes to 156.81% higher than SMA200.
C4 Therapeutics Inc (NASDAQ: CCCC) currently have 48.97M outstanding shares and institutions hold larger chunk of about 91.73% of that.
The stock has a current market capitalization of $433.66M and its 3Y-monthly beta is at 3.02. It has posted earnings per share of -$2.75 in the same period. It has Quick Ratio of 7.39 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CCCC, volatility over the week remained 12.42% while standing at 10.25% over the month.
Analysts are in expectations that C4 Therapeutics Inc (CCCC) stock would likely to be making an EPS of -$0.68 in the current quarter, while forecast for next quarter EPS is -$0.53 and it is -$2.36 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.87 which is -$0.44 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.77 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 26.22% while it is estimated to decrease by -2.20% in next year. EPS is likely to grow at an annualized rate of 22.30% for next 5-years, compared to annual growth of -46.29% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on January 29, 2024 offering a Neutral rating for the stock and assigned a target price of $6 to it. Coverage by Stifel stated C4 Therapeutics Inc (CCCC) stock as a Buy in their note to investors on December 13, 2023, suggesting a price target of $12 for the stock. On February 24, 2023, Credit Suisse Upgrade their recommendations, while on February 24, 2023, JP Morgan Downgrade their ratings for the stock with a price target of $5. Stock get a Neutral rating from JP Morgan on November 04, 2022.
